
Web Release Date: April 4,
Enzymatic Process for the Synthesis of cis/trans-(1R,5R)-Bicyclo[3.2.0]hept- 6-ylidene-acetate: Solvent Effect and NMR Study




and
Biotransformations Group, Chemical R&D, Pfizer Global R&D, 10578 Science Center Drive, San Diego, California 92121, U.S.A., and Chemical R&D, Pfizer Global R&D, Ramsgate Road, Sandwich, England
Received for review February 20, 2006.
Abstract:
An efficient enzymatic process has been developed to resolve a diastereomeric mixture of racemic ethyl bicyclo[3.2.0]hept-6-ylidene-acetate (1). Using 40% acetone, not only was the enantioselectivity of Candida antarctica lipase B (CAL-B) significantly improved to E > 200 from E = 2.7, remarkably the enzyme is able to maintain low diastereoselectivity for the Z (cis)- and E (trans)-isomers leading to an overall high isolated yield (40-45%, vs maximum theoretical yield 50%) and excellent enantiomeric excess (>98.5% ee). Preliminary studies using 2D TROSY shows that there is probably a global conformational change in the N15-labeled enzyme CAL-B when the content of organic cosolvents increases from 0% to 30%. The route was successfully scaled to 63 kg for the synthesis of GABA analogues.
(1R,5R)-Bicyclo[3.2.0]hept-6-ylidene-acetic acid (2) is a
key intermediate toward the synthesis of GABA (
-aminobutyric acid) analogues such as 3, therapeutically useful
agents for the treatment of epilepsy and neuropathic pain
(Scheme 1).1 To our knowledge, no asymmetric synthesis
of this molecule has been reported prior to this study. We
describe here the development of an efficient and cost-effective enzymatic process to prepare enantiomerically pure
E/Z-2 by the resolution of racemic and E/Z-ethyl bicyclo[3.2.0]hept-6-ylidene-acetate (1). In this method, both the
E- and Z-isomers of the (1R,5R)-enantiomer (2) are desired
to be converted into 3 (Scheme 1). While enzymes have been
widely used for the resolution of racemic molecules, this is
a rare example where the resolution involves a mixture of
four stereoisomers rendering the problem much more challenging and interesting.
| Scheme 1 |
Enzyme Screening. The racemic and E/Z-ethyl bicyclo[3.2.0]hept-6-ylidene-acetate (1) was synthesized from bicyclo[3.2.0]heptan-6-one according to a literature protocol (see
Experimental Section for details).1 Using an automated
enzyme screening protocol developed in our lab,2 Candida
antarctica lipase B (CAL-B) was one of the few enzyme
candidates identified that was able to catalyze the hydrolysis
of the ethyl ester with some selectivity and high reactivity.
Unfortunately, the enantioselectivity of the enzyme was quite
low (E = 2.7, or 33% ee at a conversion of 50%) under
Medium Study. Attempts at improving the enantioselectivity of the enzyme were made via medium engineering. After screening a number of representative solvents with log P values ranging from -1 to 5 and various cosolvent contents from 20% to 50%, it was found that t-BuOH (log P 0.35), acetonitrile (log P -0.34), and acetone (log P -0.24) have the desired physical properties to tune the enantioselectivity of the enzyme. Figure 1 and Figure 2 illustrate in more detail the effect of these solvents on the reactivity and enantioselectivity of CAL-B towards the substrate 1. As the cosolvent content was increased from 20% to 50%, the ee's increased from 78% to 98.1% for t-BuOH, 85% to 95% for acetone, and 92.4% to 98.5% for ACN (Figure 2). At the same time, the rate of the reaction decreased for all three cosolvents (Figure 3). Therefore, a dramatic solvent effect was observed, where not only was the enantioselectivity significantly improved to E > 200, but remarkably the enzyme was also able to maintain low diastereoselectivity for the E- and Z-isomers as well. This was essential to maximize the overall yield of the reaction because both the E- and Z-(1R,5R)-2 will be turned into the same intermediate for the synthesis of 3. Acetone (40%) is ideal for further process development since it allows us to achieve the desired enantioselectivity and maintains a high reactivity (98.1% ee, 37.7% conversion at pH7 after 16 h). Acetone is also inexpensive and easier to handle at large scale for both the reaction and downstream separation.
pH Effect. As the pH changes from 5.0 to 8.0, the rate of the reaction increases without any sacrifice to enantioselectivity (Figure 3). At pH's higher than 8.5, a decrease in ee's is observed presumably due to background chemical hydrolysis. The optimal pH was chosen at 8.0.
Temperature Effect. Temperature optimization studies
were carried out from 30 to 60
C. As seen from Figure 4,
temperature has a minor effect on both the reactivity and
enantioselectivity of the reaction. Therefore, all subsequent
reactions were run at room temperature for higher process
efficiency.
Enzyme Sources. To identify the ideal CAL-B form for process development, different forms of the enzyme from various suppliers were selected for comparison including Chirazyme L2 solution from Roche, Novozyme 435 from Novozyme, cross-linked enzyme crystal (CLEC) CAL-B from Altus, Chirazyme L2 Carrier Fixed (C.F.) from Roche, and Chirazyme L2 Lyo powder from Roche). All forms of CAL-B showed similar reactivity and price profile except for the CLEC and the Chirazyme L2 C.F., which are less reactive. In general, the lypophilized forms are substantially more expensive than the crude extracts. Ultimately, Novozyme 435 was selected, as it can be readily recycled to further enhance the process efficiency, resulting in simpler workup and reduction in the cost of goods.
Enzyme Recycling Studies. Novozyme 435 is an immobilized form of CAL-B through physical absorption to
the macroporous acrylic resin. Therefore, solvents will have
a strong effect on enzyme leaching and its residual activity
after solvent incubation. Among the eight solvents studied,
acetonitrile has the strongest negative effect on leaching
(Figure 5). Over 70% of the activity was lost after incubation
in 40% acetonitrile for 16 h compared to the nonincubated
control (Novo 435 Ctl, Figure 5). In contrast, in 40% acetone,
not only does CAL-B retain most of its activity (70%) after
one recycle run, it is also more active than other solvents
under the same cosolvent content (see Medium Study
section). Essentially no loss in activity was observed in 100%
t-BuOH for this form of CAL-B. It should also be noted
that the same enzyme retains almost 87% of the activity after
incubation and recycling from 100% aqueous phosphate
buffer. On the other hand, pH does not have a significant
effect on the recycling of Novozyme 435, and pH 8.0 was
chosen due to the high activity of CAL-B under the condition
(Figure 6). Temperature has a strong effect on the leaching
and residual activity of Novozyme 435, which lost almost
75% of the activity after incubation in a buffer at 50-60
C
for 16 h (Figure 7). Therefore, the reaction should be
conducted at room temperature.
Process Description. Under the optimal reaction conditions (Novozyme 435, 40% acetone, pH 8.0, rt), the reaction was initially demonstrated at 100-g scale. With a substrate loading of 100 g/L and an enzyme loading of 25 g/L, the reaction reached 45-50% conversion in a batch reactor controlled by an auto pH titrator within 24 h. After filtration of the immobilized enzyme, the desired mixture of E/Z-(2R,5R)-bicyclo[3.2.0]hept-6-ylidene-acetate (2) was isolated with a yield of 40-45% and 98.5% ee (E > 200 at a conversion of 49%) after removal of the leftover E/Z-enantiomer 4 (Scheme 2) (for details see Experimental Section). Both the E/Z-2 was carried on to the next step for the synthesis of 3 without further purification. The immobilized enzyme was recycled for the next batch of hydrolytic resolution, leading to lower material cost. Subsequently, the enzymatic process was successfully scaled up to 62.8 kg scale with a reaction volume of 630 L in a 1450-L glass-lined reactor.
| Scheme 2 |
NMR Study of the Solvent Effect. Due to the dramatic
solvent effect observed in this case, and the dynamic nature
of enzymatic catalysis, we decided to prepare the N15-labeled
CAL-B and use NMR to monitor the change of the protein
backbone as the content of solvent is increasing. While it is
known that solvents have strong effects on both reactivity
and enantioselectivity, the fundamental mechanism is still
not clear,3,4
The challenge in this process was to identify an enzyme that is selective towards both the E- and Z- diastereomers of one enantiomer leaving behind the E/Z isomers of the other enantiomer. The only enzyme identified upon screening was Candida antarctica lipase B, but it exhibited an E value of only 2.7 under screening conditions with 10% organic cosolvent. Comprehensive medium engineering yielded a dramatic effect, improving the E value of CAL-B to >200 towards this substrate using 40% acetone. This process was further optimized using an immobilized CAL-B to reduce the cost of goods by enzyme recycling and to enhance process efficiency through simpler workup. Finally the enzymatic transformation was successfully scaled up to 62.8 kg scale in a batch reactor. This process represents the first synthesis of enantiomerically pure E/Z-(2R,5R)-bicyclo[3.2.0]hept-6-ylidene-acetic acid, a key intermediate needed for the preparation of GABA analogues. This is a rare example where enzymatic resolution involved four stereoisomers and the success resulted from a strong solvent effect. A preliminary 2D NMR study using N15-CAL-B indicates the organic solvent probably has a global effect on the change of protein conformation.
General Procedure. For a general procedure of enzyme
screening in a 96-well plate please see ref 2. The majority
of enzymes utilized in the preparation of screening kits were
obtained from various enzyme suppliers including Amano
(Nagoya, Japan), Roche (Basel, Switzerland), Novozymes
A/S (Bagsvaerd, Denmark), Altus Biologics Inc. (Cambridge,
MA), Biocatalytics (Pasadena, CA), Toyobo (Osaka, Japan),
Sigma-Aldrich (St. Louis, MO). Reactions were performed
in an Eppendorf thermomixer-R (VWR), and HPLC analysis
was carried out by an Agilent 220 HPLC autosampler.
Solvents were obtained from EM Science (Gibbstown, NJ)
and were of the highest purity available. All reactions
involving air-sensitive reagents were performed under dry
nitrogen. All materials obtained from commercial suppliers
were used without further purification. 1H NMR spectra were
recorded at 400 MHz on a Varian Mercury spectrometer with
the solvent as an internal standard (
H: CDCl3 7.26 ppm).
13C NMR spectra were recorded at 75 MHz on a Varian
Inova spectrometer with the solvent as the internal standard
(
C: CDCl3 77.03 ppm). Chiral purity was measured by
HPLC employing a Chiralpak AS-RH (4.6 mm × 150 mm)
at a column temperature of 20
C and UV wavelength of
225 nm. The gradient elution is tabulated below, and the
flow rate was 0.7 mL/min. Sample concentration was 1 mg/mL, and the retention times were observed as follows;
(1R,5R,E)-bicyclo[3.2.0]hept-6-ylideneacetic acid 12.1 min;
(1R,5R,Z)-bicyclo[3.2.0]hept-6-ylideneacetic acid 12.7 min;
(1S,5S,E)-bicyclo[3.2.0]hept-6-ylideneacetic acid 13.5 min;
(1S,5S,Z)-bicyclo[3.2.0]hept-6-ylideneacetic acid 18.0 min.
Ethyl Bicyclo[3.2.0]hept-6-ylideneacetate (1). Bicyclo[3.2.0]hept-2-en-6-one (42 kg, 388 mol) was dissolved in
n-heptane (82 L), and 5% Pd/C (50% wet, 0.12 kg) was
added. The reaction mixture was hydrogenated at 30 psi
(1551 Torr) of hydrogen and 30
C for 8 h. The reaction
mixture was filtered, and the vessel and catalyst residue were
washed with n-heptane (20 L). The filtrate was then used
directly in the next step without further purification. Separately, to a suspension of sodium ethoxide (27.2 kg, 400 mol)
in n-heptane (107 L) was added triethylphosphonoacetate
(95.9 kg, 428 mol) over 1 h, maintaining the temperature at
45
C. The reaction mixture was then stirred at -45
C
for 75 min. The solution of bicyclo[3.2.0]heptan-6-one in
n-heptane (388 mol) from the previous step described above
was added over 2.5 h, maintaining the temperature at -48
to -38
C. The reaction mixture was then stirred at - 45
C for 2 h and quenched with a 25% aqueous solution of
hydrochloric acid (80 L). The phases were allowed to warm
to room temperature and then separated. To the n-heptane
phase was added a 17.6% Na2CO3 solution in water (375
kg) prepared by dissolving Na2CO3 (66 kg, 623 mol) in water
(309 L). The mixture was stirred for 10 min, and the phases
were separated. To the n-heptane phase was added water
(202 L), the mixture was stirred for 10 min, and the phases
were separated. The organic phase was concentrated in vacuo
to give the product (60.8 kg, 337 mol) in 87% yield as a
slightly yellowish oil (Z:E ratio typically >4:1): 1H NMR
(400 MHz, CDCl3)
5.58-5.55 (m, 1H, Z isomer), 5.54-5.52 (m, 1H, E isomer), 4.20 (q, 2H, E isomer), 4.14 (q,
2H, Z isomer), 3.76-3.70 (m, 1H, E isomer), 3.41-3.35 (m,
1H, Z isomer), 3.25-3.15 (m, 1H, Z isomer), 2.90-2.82 (m,
1H, E + Z isomers), 2.60-2.50 (m, 1H, Z isomer), 2.30-2.20 (m, 1H, E isomer), 2.05-1.97 (m, 1H, E isomer), 1.80-1.50 (m, 6H, E + Z isomers), 1.28 (t, 3H, E + Z isomers)
in agreement with literature data.1
Kcat Measurement. The Z-(1R,5R)-ethyl bicyclo[3.2.0]hept-6-ylidene-acetate was prepared by prep-HPLC, and its
concentrations were varied from 8 to 5000
M in the
presence of 5
L of CAL-B (20.6
M). After 3 min, the
reaction was quenched by the addition of a 10% 3.2%-TFA
solution. Kcat and Km were calculated using the Kaleidagraph
3.5 program. In the presence of 10% acetonitrile at room
temperature, Vmax = 59.4
M/min or Km = 303
M and Kcat
= 115 min-1.
(1R,5R,E)-Bicyclo[3.2.0]hept-6-ylideneacetic Acid (Z-2). To a reaction flask equipped with a pH electrode, an
overhead stirrer, and a base addition line controlled by a 718
Stat titrino-metrohm pH titrator was added acetone (400 mL)
and potassium phosphate buffer (pH = 7.2, 600 mL). The
pH of the resulting mixture was adjusted to pH 8.0, and 25
g of Novozyme 435 was added. The suspension was then
stirred at room temperature for 1 min, and the racemic ethyl
ester 1 (100 g) was added to the mixture. The reaction was
monitored by RP-HPLC looking at both the conversion and
ee's of the product, and was stopped after about 45-50%
of the starting material had been consumed (approximately
24 h). After the reaction was complete, the heterogeneous
mixture was filtered to recover the immobilized enzyme. The
reaction mixture was concentrated under vacuum to remove
the 400 mL of acetone. The aqueous solution was then
acidified to pH 4.0 with 1 N HCl, and extracted three times
with MTBE. The acid and ester fractions were pooled, dried
with sodium sulfate, and concentrated by rotary evaporation.
A vacuum distillation was then carried out to separate the
acid product 2 as a E/trans mixture (>98.5% ee by chiral
HPLC with 40-45% yields) from the residual ester: 1H
NMR (400 MHz, CDCl3)
5.58-5.55 (m, 1H, Z isomer),
5.54-5.52 (m, 1H, E isomer), 3.77-3.70 (m, 1H, E isomer),
3.43-3.35 (m, 1H, Z isomer), 3.26-3.16 (m, 1H, Z isomer),
2.91-2.82 (m, 1H, Z isomer), 2.61-2.51 (m, 1H, Z isomer),
2.32-2.22 (m, 1H, E isomer), 1.83-1.51 (m, 6H, E + Z
isomers). 13C NMR (75 MHz, CDCl3)
175.2, 172.5, 112.5,
48.9, 37.5, 35.7, 33.1, 32.5, 24.6.
Alternatively, the product can be obtained by an acid/base workup (62.8-kg scale): the enzyme was removed by
filtration using a centrifuge after the reaction was finished
from an initial set up with 62.8 kg of racemic E/trans-ethyl
bicyclo[3.2.0]hept-6-ylideneacetate in 248 L of acetone and
512 L of buffer. The enzyme was washed with n-heptane
(313 L), and the pH of the filtrate was adjusted to pH 2
using concentrated hydrochloric acid (15.5 L). The aqueous
layer was separated and extracted with MTBE (150 L). The
combined organic layers were extracted with 1 N NaOH (121
L) and the layers separated. The organic phase was extracted
a second time with 1 N NaOH (50 L), and the layers were
separated. The combined basic aqueous layers were washed
twice with n-heptane (2 × 54 L) to remove the starting
material. The pH of the aqueous phase was then adjusted to
pH 1-2 using 36% commercial grade concentrated hydrochloric acid (30 L) and extracted twice with MTBE (2 ×
155 L). The combined MTBE extracts were then washed
with water (100 L) and concentrated in vacuo to give the
crude product (17.2 kg) raw as a pale-yellow oil, which can
be further purified as a white powder by crystallization in
ethanol-water (2.2:3.4 v/v) with a melting point of 68
C
by DSC.
N15-CAL-B Cloning, Expression, and Purification. The genomic DNA was isolated from Candida antarctica (ATCC 32657) and the CAL-B gene amplified by PCR (polymerase chain reaction) using primers CTTCGAATTCCTACCTTCCGGTTCGGACC and GCGGATACAGCGGCCGCGGGGGTGACGATGCCGGAG (see ref 8). The protein was cultured and expressed in Pichia pastoris using a pPIC9 vector. The CAL-B construct was transformed into GS115 strain. Transformants were screened for mut+ phenotype following manufacturer's recommended protocol (Invitrogen product manual, CA). In general, a single colony was inoculated into 25 mL of culture media and grown until OD 2-6 (18-24 h). The cells were then spun down, and the pellet was resuspended to an OD of 1.0 in minimal media to induce expression. Methanol was then added every 24 h (1%), and the culture was induced for 72 h (for details, see the Invitrogen manual). The media supernatant was tested for the activity using the ethyl ester 1. Once the activity of the CLA-B was confirmed, steps were taken to minimize degradation by changing growth media to BMG media (phosphate buffer, pH6.0). One set was grown in the absence of exgenous isotopes, and the other was grown with 15NH4Cl (3 g/L) (see ref 10). Isotope labeled cultures demonstrated comparable expression (data not shown). The protein content was determined using a Bradford assay and was estimated to have an expression of 15 mg/L of cultures. Using a 1-mL butyl sepharose column, 500 mL of the filtered protein-containing media was purified. For purification, ammonium acetate was added to the supernatant to reach final concentration of 0.8 M. Onto a 1-mL butyl sepharose column, was loaded 500 mL of the sample without concentration. The supernatant was applied to the butyl sepharose column and eluted with a gradient of 0.8 M ammonium acetate in phosphate buffer (50 mM) and water. The eluted fractions were tested for activity, and fractions containing the desired purity (B10-A11) were pooled to get a total of 2 mg of N15-CAL-B.
NMR Analysis. NMR spectra were recorded at 30
C
using a Bruker-Biospin AV700 spectrometer operating at 700
MHz for 1H and equipped with a 5 mm TCI z-gradient
Cryoprobe. TROSY (transverse relaxation optimized spectroscopy) data were acquired using the Bruker pulse sequence
trosyf3gpphsi19 (see refs 6-7); 256 t1 increments were
collected using 128 acquisitions per increment, and 4096 t2
data points. Prior to Fourier transformation, each dimension
was apodized by a 90 degree shifted sine-bell function and
zero-filled in t1 to form a final matrix size of 2048 × 512.
Data processing and acquisition were performed using the
TOPSPIN 1.3 software package (Bruker-Biospin). Proton
chemical shifts are referenced to internal 3-(methylsilyl)
propane-1,1,2,2,3,3,-d6-sulfonic acid sodium salt (DSS). The
15N chemical shifts are referenced indirectly to DSS using
the absolute frequency ratios.
We thank Carlos Martinez, Jean Xie, and Matthew Bernett for helpful discussions and Dr. K. Fabian and Lanxess for help in process developing and scaling up.
* Author for correspondence. Telephone: (858) 518-4484. Fax: (858) 678-8199. E-mail: junhua_tao@yahoo.com.
Biotransformations Group, Chemical R&D, Pfizer Global R&D.
Chemical R&D, Pfizer Global R&D.
1. (a) Gladwell, I. R.; Pettman, A. J. WO 2004031115. (b) Derrick, A. M.
WO 2004031124. (c) Ghosez, L.; Montaigne, R.; Roussel, A.; Vanlierde,
H.; Mollet, P. Tetrahedron 1971, 27 (3), 615-33.![]()
2. Yazbeck, D.; Tao, J.; Martinez, C.; Kline, B.; Hu, S. Adv. Synth. Catal.
2003, 345 (4), 524-532.![]()
3. Schmitke, J. L.; Stern, L. J.; Klibanov, A. M. Proc. Natl. Acad. Sci. U.S.A.
1998, 95, 12918-12923.![]()
4. Laane, C.; Boeren, S.; Vos, K.; Veeger, C. Biotechnol. Bioeng. 1987, 81-87.![]()
5. For NMR studies using nonlabeled CAL-B, see: (a) Vallikivi, I.; Järving,
I.; Pehk, T.; Samel, N.; Tõugu, V.; Parve, O. J. Mol. Cat. B 2004, 32, 15-19.
(b) Hansen, T. V.; Waagen, V.; Partali, V.; Anthonsen, H. W.;
Anthonsen, T. Tetrahedron: Asymmetry 1995, 6, 499-504.![]()
6. Pervushin, K.; Wider, G.; Wuethrich, K. J. Biomol. NMR 1998, 1, 345-348.
7. Rance, M.; Loria, J. P.; Palmer, A. G., III. J. Magn. Reson. 1999, 136,
91-101.
8. Uppenberg, J.; Hansen, M. T.; Patkar, S.; Jone, T. A. Structure 1994, 2,
293-308.![]()
9. For a literature protocol, see: Rotticci-Mulder, J. C.; Gustavsson, M.;
Holmquist, M.; Hult, K.; Martinelle, M. Protein Express. Purif. 2001, 21,
386-392.![]()
10. Pickford, A. R.; O'Leary, J. M. Methods Mol. Biol. 2004, 278, 17-33.![]()
|
time (min) |
0.1% TFA/acetonitrile (%) |
0.1% TFA/water (%) |
|
0.00 |
30 |
70 |
|
15.00 |
30 |
70 |
|
22.00 |
10 |
90 |
|
23.00 |
30 |
70 |
|
33.00 |
30 |
70 |